Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands.
J Neurol. 2012 Dec;259(12):2519-26. doi: 10.1007/s00415-012-6510-x. Epub 2012 May 3.
Focal dystonia is a common, invalidating neurologic condition characterized by involuntary, sustained muscle contractions causing twisting movements and abnormal postures in one body part. Currently, botulinum toxin is the treatment of first choice. We performed a systematic review towards the pharmaco-therapeutic and pharmaco-economic value of botulinum toxin as treatment for focal dystonia, which yielded the following results. Botulinum toxin is the most effective treatment for reducing dystonic symptoms measured with dystonia-specific and general questionnaires, and pain in patients with focal dystonia. Seventy-one percent of patients with cervical dystonia had a reduction in neck pain compared to 12 % in placebo groups. Adverse events occur in 58 % of patients during treatment with botulinum toxin compared to 46 % treated with placebo. Especially dry mouth, neck weakness, dysphagia, and voice changes are common. Adverse events are usually mild and self-limiting. Health-related quality of life, measured with the SF-36 is 20-50 points lower in patients with focal dystonia compared to controls and the effect of botulinum toxin on health-related quality of life is unclear. Botulinum toxin treatment is expensive because the drug itself is expensive. Yearly costs for treating a patient with focal dystonia with botulinum toxin range from EUR 347 to EUR 3,633 and the gain in QALYs with BTX treatment is small. Focal dystonia impairs the productivity and the ability to work. At start of botulinum toxin treatment only 47-50 % was working. Botulinum toxin partly improves this. Overall, we conclude that botulinum toxin is an expensive drug with good effects. From a societal perspective, the costs may well weigh up to the regained quality of life. However, the available literature concerning costs, health-related quality of life and labor participation is very limited. An extensive cost-effectiveness study should be performed incorporating all these aspects.
局限性肌张力障碍是一种常见的、使人丧失能力的神经系统疾病,其特征是身体某一部位的不随意、持续的肌肉收缩导致扭曲运动和异常姿势。目前,肉毒毒素是首选的治疗方法。我们对肉毒毒素治疗局限性肌张力障碍的药物治疗和药物经济学价值进行了系统评价,结果如下。肉毒毒素是治疗局限性肌张力障碍最有效的方法,可降低使用特定于肌张力障碍和一般问卷测量的肌张力障碍症状和疼痛。与安慰剂组 12%的患者相比,71%的颈肌张力障碍患者的颈部疼痛减轻。与接受安慰剂治疗的患者相比,58%接受肉毒毒素治疗的患者出现不良反应。特别是口干、颈部无力、吞咽困难和声音改变较为常见。不良反应通常为轻度且自限性。使用 SF-36 测量,局限性肌张力障碍患者的健康相关生活质量比对照组低 20-50 分,肉毒毒素对健康相关生活质量的影响尚不清楚。由于药物本身昂贵,肉毒毒素治疗费用昂贵。用肉毒毒素治疗一名局限性肌张力障碍患者的年费用为 347-3633 欧元,BTX 治疗带来的 QALY 增益很小。局限性肌张力障碍会影响生产力和工作能力。在开始肉毒毒素治疗时,只有 47-50%的患者在工作。肉毒毒素在一定程度上改善了这一点。总的来说,我们得出的结论是,肉毒毒素是一种昂贵的药物,但其疗效良好。从社会角度来看,这些成本很可能与恢复的生活质量相平衡。然而,关于成本、健康相关生活质量和劳动参与的现有文献非常有限。应该进行一项包含所有这些方面的广泛的成本效益研究。